THE EFFECTS OF THIAZOLIDINEDIONES ON BONE MINERAL DENSITY IN PATIENTS WITH TYPE 2 DIABETES MELLITUS

Abstract

Osteoporosis is a disease characterized by low bone mass and microarchitectural deterioration of bone tissue leading to enhanced bone fragility and a consequent increase in fracture risk. Certain medications have been associated with an increased osteoporosis risk. Thiazolidinediones, have been linked with an increased risk of osteoporosis and fracture. The aim of the present study is to evaluate the effects of thiazolidinediones on bone mineral density in the patients with type 2 diabetes mellitus. 54 patients (36 women and 18 men) with type 2 diabetes mellitus were recruited for this study. The subjects were between 53 and 68 years. The bone mineral density (BMD) was measured by dual-energy X-ray absorptiometry (DXA). 26 patients followed thiazolidinediones therapy and 28 patients followed sulfonylurea and metformin treatment. The mean (± SD) T-score on hip was 2.20 ± 0.36 in patients using thiazolidinediones therapy, and on lumbar spine was 2.22 ± 0.24. In patients using sulfonylurea and metformin treatment the mean (± SD) T- score on hip was 2.18 ± 0.22 and on lumbar spine was 2.18 ± 0.28. o changes have been observed in the average values of BMD on hip and lumbar spine in patients using thiazolidinediones therapy compared with patients using sulfonylurea and metformin treatment.